EPIC(Effect of PhosLo on Phosphorus Levels in Chronic Kidney Disease)

Status Completed

Clinical Trial Summary

The purpose of this study is to determine if calcium acetate (PhosLo) can control serum phosphorus in pre-dialysis patients with moderate to severe impairment of kidney function.

Clinical Trial Description

In patients with impaired kidney function, dietary phosphorus can not be completely excreted, which leads to elevated levels of serum phosphorus. Elevated serum phosphorus leads to increased levels of parathyroid hormone (PTH), and is associated with bone disease and other adverse consequences such as soft-tissue and vascular calcification, and increased morbidity and mortality. It is therefore important to prevent hyperphosphatemia and maintain serum phosphorus levels within the range recommended by K/DOQI. In patients on dialysis, phosphate binders are routinely used to control serum phosphorus by absorbing dietary phosphate during the transit through the intestine. However, the use of phosphate binders for non-dialyzed patients with chronic kidney disease (CKD) is not an FDA approved indication, although some physicians treat patients prior to dialysis based on clinical judgment. The goal of this study is to demonstrate the efficacy of calcium acetate (PhosLo) in controlling serum phosphorus in patients with moderate to severe decrease in kidney function. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00211978
Study type	Interventional
Source	Nabi Biopharmaceuticals
Contact
Status	Completed
Phase	Phase 3
Start date	May 2005
Completion date	October 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04510090` - Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus	Phase 1
Completed	`NCT02546037` - Clotting With Different Dialyzer Membranes
Recruiting	`NCT02545920` - To Assess Ear Blood Flow During Dialysis
Completed	`NCT02134314` - C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI	Phase 1/Phase 2
Recruiting	`NCT01912001` - Virtual Ward for Home Dialysis	N/A
Completed	`NCT01158742` - Live Kidney Donor Study -Renal Function Study	N/A
Completed	`NCT00986947` - Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates	Phase 2
Completed	`NCT00765661` - Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients	Phase 2
Withdrawn	`NCT00807274` - Renal Function in Adults With Congenital Heart Disease.	N/A
Completed	`NCT00369382` - Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients	Phase 4
Completed	`NCT00183248` - Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients	Phase 1/Phase 2
Enrolling by invitation	`NCT05324878` - Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
Completed	`NCT05272800` - BIS-guided Fluid Management in HD Patients	N/A
Completed	`NCT03836508` - Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis	N/A
Completed	`NCT01756508` - Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury	Phase 2
Completed	`NCT03723668` - Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
Recruiting	`NCT04277377` - Nanoparticle for DSA Removal
Terminated	`NCT00450333` - Dynepo Infrequent Dosing Study	Phase 3
Terminated	`NCT03840343` - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease	Phase 1
Recruiting	`NCT04714853` - Different Dialysis Modalities and Diet on Gastrointestinal Biome and Azotaemic Toxins